<HashMap><database>GEO</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Other>ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE117nnn/GSE117856/</Other></files><type>primary</type></body><statusCode>OK</statusCode><statusCodeValue>200</statusCodeValue></file_versions><scores/><additional><omics_type>Transcriptomics</omics_type><species>Homo sapiens</species><gds_type>Expression profiling by high throughput sequencing</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE117856</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>RNAseq from MDA-MB-231 shYB-1 and sh control</name><description>Elevated YB-1 expression correlates with poor patient survival and drug resistance in diverse tumor types, notably in metastatic tumors. In this report, we characterized the role of YB-1 in breast tumor initiation and progression, in primary cells or cell lines. Notably, YB-1 blockade in MDA-MB-231 cells shown that YB-1 has a major role in tumor progression and dissemination, but not in in vitro settings. Our data suggests induction of YB-1 expression is associated with the activation of a HIF1α program.</description><dates><publication>2026/07/08</publication></dates><accession>GSE117856</accession><cross_references><GSM>GSM3311569</GSM><GSM>GSM3311568</GSM><GSM>GSM3311567</GSM><GSM>GSM3311566</GSM><GSM>GSM3311565</GSM><GSM>GSM3311564</GSM><GSM>GSM3311563</GSM><GSM>GSM3311570</GSM><GPL>16791</GPL><SRA>SRP155737</SRA><GSE>117856</GSE><taxon>Homo sapiens</taxon><PMID>[34294889]</PMID></cross_references></HashMap>